Results 251 to 260 of about 161,793 (289)

Beyond the DNA sequence: mapping the dynamic epigenetic landscape for risk stratification and therapeutic intervention in acute myeloid leukemia. [PDF]

Clin Exp Med
Xie J, Soleimani Samarkhazan H.
europepmc   +1 more source

Immunophenotypically Defined Mixed-Phenotype Acute Leukemias: A Clinicopathologic Analysis of 52 Cases. [PDF]

EJHaem
Zhang B, Weinberg OK, Chen W, Fuda F, Chen M, Germans SK.   +5 more
europepmc   +1 more source

Metachronous Presentation of BCL-2-Positive Lung Adenocarcinoma and Acute Myeloid Leukemia: A Case Presentation and Review of the Literature. [PDF]

Case Rep Oncol
Zhang Y, Zheng B, Yi K, Pang T, Zhu L, Zhou J, Xu C, He J, Xu C, Chen J, Yu M, Chen M, Chen C, Lan H, Li R.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

AML-388: KDM6A Mutation in AML

Clinical Lymphoma Myeloma and Leukemia, 2020
Introduction Loss of KDM6A expression has been reported as a potential drug resistance mechanism in AML. Here, we describe the clinical characteristics and treatment outcomes in our cohort of AML patients with KDM6A mutations. Methods We annotated a cohort of 293 AML patients who were treated at our center between Jan 2016 and Dec 2019.
Vijendra Singh, Omar Albanyan, Suresh Balasubramanian, Seongho Kim, Jay Yang   +4 more
openaire   +1 more source

Reasons for treating secondary AML as de novo AML

European Journal of Haematology, 2010
AbstractIn a Danish bi‐regional registry‐based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML.
Ostgård, Lene Sofie Granfeldt, Kjeldsen, Eigil, Holm, Mette Skov, Brown, Peter De Nully, Pedersen, Bjarne Bach, Bendix, Knud, Johansen, Preben, Kristensen, Jørgen Schøler, Nørgaard, Jan Maxwell   +8 more
openaire   +4 more sources

Immunotherapy of AML

2009
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6].
Gheath, Alatrash, Jeffrey J, Molldrem
openaire   +2 more sources

Epigenetics in AML

Best Practice & Research Clinical Haematology, 2010
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire   +2 more sources

Secondary AML and AML-MRC

2020
Seongseok Yun, David A. Sallman, Jeffrey E. Lancet   +2 more
openaire   +1 more source